NCT03655353View on ClinicalTrials.gov

A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2025

Conditions
HER2-positive Breast Cancer
Interventions
DIAGNOSTIC_TEST

ABY-PET

Diagnostic PET for HER2 expression

Trial Locations (1)

75185

RECRUITING

Section for Clinical Research & Development Unit, Uppsala

Sponsors

Collaborators (1)

Affibody
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Swedish Cancer Society

OTHER

collaborator

Affibody

INDUSTRY

collaborator

Swedish Breast Cancer Group

OTHER

lead

Henrik Lindman

OTHER